Montanova Capital, LLC
About Montanova Capital, LLC’s 13F portfolio
Montanova Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Montanova Capital, LLC reported $4.8B across 95 US-listed positions (). Its largest position is VERADERMICS INC (MANE) at 11% of the reported book, and its ten biggest holdings make up 45% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: MANE VERADERMICS INC | — — | 11% | 4.2M | $512.5M |
| 2 | NASDAQ: ARQT ARCUTIS BIOTHERAPEUTICS INC | $27.17 −1.59% | 6.9% | 12.4M | $326.1M |
| 3 | NASDAQ: LEGN LEGEND BIOTECH CORP | $16.10 −0.92% | 4.3% | 7.1M | $204.2M |
| 4 | NASDAQ: PVLA PALVELLA THERAPEUTICS INC NE | $145.77 −0.55% | 3.6% | 1.1M | $173.5M |
| 5 | NASDAQ: AVBP ARRIVENT BIOPHARMA INC | $11.26 +3.30% | 3.3% | 4.5M | $156.9M |
| 6 | NASDAQ: BNTC BENITEC BIOPHARMA INC | $8.14 −1.57% | 3.2% | 11.5M | $154.5M |
| 7 | NYSE: BHVN BIOHAVEN LTD | $13.65 +5.81% | 3.2% | 10.3M | $153.1M |
| 8 | NASDAQ: AMD ADVANCED MICRO DEVICES INC | $489.19 −7.72% | 3.1% | 257K | $149.4M |
| 9 | NYSE: RCUS ARCUS BIOSCIENCES INC | $15.78 +0.13% | 3.1% | 4.8M | $147.3M |
| 10 | NYSE: TSM TAIWAN SEMICONDUCTOR MANUFAC | $352.09 −2.90% | 3.1% | 305K | $145.5M |
| 11 | NASDAQ: NVDA NVIDIA CORPORATION | $145.98 −3.30% | 3.0% | 721K | $144.2M |
| 12 | NASDAQ: EYPT EYEPOINT INC | $0.26 −2.87% | 2.5% | 8.3M | $118.6M |
| 13 | NYSE: SYY SYSCO CORP | $77.15 −0.99% | 2.5% | 1.4M | $118.0M |
| 14 | NYSE: GE GE AEROSPACE | $318.88 −2.81% | 2.4% | 310K | $116.0M |
| 15 | NASDAQ: IMTX IMMATICS N.V | $5.95 −2.46% | 2.4% | 11.2M | $113.4M |
| 16 | NYSE: MGM MGM RESORTS INTERNATIONAL | $33.41 −0.98% | 2.3% | 2.3M | $111.2M |
| 17 | NASDAQ: META META PLATFORMS INC | $596.22 −3.27% | 2.1% | 176K | $99.0M |
| 18 | NASDAQ: CAPR CAPRICOR THERAPEUTICS INC | $7.53 −6.23% | 2.1% | 4.1M | $98.6M |
| 19 | NASDAQ: KURA KURA ONCOLOGY INC | $7.35 +0.14% | 2.0% | 8.6M | $94.1M |
| 20 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | $8.91 −1.76% | 1.8% | 3.5M | $85.9M |
| 21 | NASDAQ: AVLN AVALYN PHARMACEUTICALS INC | — — | 1.7% | 2.5M | $82.4M |
| 22 | NYSE: HD HOME DEPOT INC | $336.68 −0.28% | 1.7% | 226K | $79.7M |
| 23 | NASDAQ: HUT HUT 8 CORP | $55.80 −2.43% | 1.6% | 670K | $77.3M |
| 24 | NYSE: COF CAPITAL ONE FINL CORP | $181.76 −1.38% | 1.4% | 333K | $66.8M |
| 25 | NYSE: VMC VULCAN MATLS CO | $274.19 −1.98% | 1.3% | 215K | $63.4M |
Showing 1–25 of 95 positions on this page reported in this 13F.
- Healthcare51%
- Technology11%
- Consumer Cyclical6.0%
- Financial Services4.9%
- Industrials3.9%
- Communication Services3.1%
- Consumer Defensive2.5%
- Basic Materials1.6%
- AddedARQTARCUTIS BIOTHERAPEUTICS INC+0.9%$326.1M
- AddedAVBPARRIVENT BIOPHARMA INC+2.6%$156.9M
- AddedTSMTAIWAN SEMICONDUCTOR MANUFAC+2.0%$145.5M
- AddedNVDANVIDIA CORPORATION+25.4%$144.2M
- AddedSYYSYSCO CORP+21.8%$118.0M
- AddedMGMMGM RESORTS INTERNATIONAL+7.7%$111.2M
- AddedMETAMETA PLATFORMS INC+3.6%$99.0M
- AddedCAPRCAPRICOR THERAPEUTICS INC+7.2%$98.6M
- NewAVLNAVALYN PHARMACEUTICALS INC—$82.4M
- AddedHDHOME DEPOT INC+2.0%$79.7M
- ReducedLEGNLEGEND BIOTECH CORP−6.7%$204.2M
- ReducedPVLAPALVELLA THERAPEUTICS INC NE−1.6%$173.5M
- ReducedRCUSARCUS BIOSCIENCES INC−5.1%$147.3M
- ReducedGLUEMONTE ROSA THERAPEUTICS INC−16.0%$85.9M
- ReducedAMZNAMAZON COM INC−19.3%$48.8M
- ReducedAPOAPOLLO GLOBAL MGMT INC−1.1%$45.3M
- ReducedBACBANK OF AMER CORP−39.0%$45.0M
- ReducedCMPXCOMPASS THERAPEUTICS INC−1.4%$30.9M
- ReducedUNHUNITEDHEALTH GROUP INC−36.3%$26.7M
- ReducedFULCFULCRUM THERAPEUTICS INC−43.9%$13.5M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | BNTC Benitec Biopharma Inc. | 13D | 44.1% | 17.8M | Filed 10 NOV 2025 |
| 2 | IFRX InflaRx N.V. | 13G | 15.6% · 2 classes | 22.9M | Filed 14 AUG 2026 |
| 3 | MOLN MOLECULAR PARTNERS AG | 13G | 10.6% | 4.3M | Filed 02 MAY 2025 |
| 4 | DBVT DBV Technologies S.A. | 13G | 9.9% | 15.2M | Filed 11 APR 2025 |
| 5 | ZURA Zura Bio Limited | 13G | 9.9% · 2 classes | 9.5M | Filed 12 MAY 2026 |
| 6 | AVBP ArriVent BioPharma, Inc. | 13G | 9.9% | 3.4M | Filed 13 AUG 2025 |
| 7 | FULC Fulcrum Therapeutics, Inc. | 13G | 9.4% | 5.1M | Filed 02 MAY 2025 |
| 8 | FTH Faeth Therapeutics, Inc. | 13G | 8.9% | 2.3M | Filed 13 NOV 2026 |
| 9 | MANE Veradermics, Incorporated | 13D | 8.8% · 2 classes | 3.7M | Filed 21 AUG 2026 |
| 10 | IMTX Immatics N.V. | 13G | 8.3% · 2 classes | 11.2M | Filed 13 FEB 2026 |
| 11 | CMPX Compass Therapeutics, Inc. | 13G | 8.2% | 14.1M | Filed 21 AUG 2025 |
| 12 | REPL Replimune Group, Inc. | 13G | 7.9% | 6.6M | Filed 06 AUG 2026 |
| 13 | BHVN Biohaven Ltd. | 13G | 7.8% | 10.3M | Filed 13 FEB 2026 |
| 14 | LXEO Lexeo Therapeutics, Inc. | 13G | 7.7% | 5.7M | Filed 13 APR 2026 |
| 15 | PVLA Palvella Therapeutics, Inc. | 13G | 7.4% | 822K | Filed 13 NOV 2025 |
| 16 | — 89bio, Inc. | 13G | 5.6% | 8.3M | Filed 13 NOV 2025 |
| 17 | GLUE Monte Rosa Therapeutics, Inc. | 13G | 5.5% | 3.4M | Filed 16 APR 2025 |
| 18 | ABEO Abeona Therapeutics Inc. | 13G | 5.2% | 2.7M | Filed 13 AUG 2025 |
| 19 | ERAS Erasca, Inc. | 13G | 5.1% | 14.5M | Filed 13 AUG 2025 |
Showing all 19 disclosed stakes. 8 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Montanova Capital, LLC’s 13F portfolio
Montanova Capital, LLC’s $4.8B 13F book is spread across 95 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 45%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are MANE, ARQT, LEGN, PVLA and AVBP, led by VERADERMICS INC (MANE) at 11% of the portfolio. The heaviest sector exposure is Healthcare (51%), then Technology (11%).
What Montanova Capital, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Montanova Capital, LLC was a net buyer: it opened 21 new positions and added to 25 more, while trimming 17 and closing 14 outright. Against a 95-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ARCUTIS BIOTHERAPEUTICS INC (ARQT), and its biggest reduction was LEGEND BIOTECH CORP (LEGN).
What a 13F does and doesn’t reveal
A 13F captures only Montanova Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Montanova Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Montanova Capital, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Montanova Capital, LLC's page?
It reflects Montanova Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Montanova Capital, LLC files its next quarterly report, this page refreshes automatically.
Can I see Montanova Capital, LLC's complete list of holdings?
This page highlights Montanova Capital, LLC's largest positions rather than all 95 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Montanova Capital, LLC's filings.
Does a 13F show everything Montanova Capital, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Montanova Capital, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Montanova Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

